Match!

Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer

Published on Oct 1, 2018in British Journal of Cancer5.416
· DOI :10.1038/s41416-018-0260-1
Ping Wang2
Estimated H-index: 2
(TUM: Technische Universität München),
Viktor Magdolen39
Estimated H-index: 39
(TUM: Technische Universität München)
+ 9 AuthorsDaniela Loessner21
Estimated H-index: 21
(QUT: Queensland University of Technology)
Sources
Abstract
Tissue kallikrein-related peptidases 4, 5, 6 and 7 (KLK4–7) strongly increase the malignancy of ovarian cancer cells. Deciphering their downstream effectors, we aimed at finding new potential prognostic biomarkers and treatment targets for ovarian cancer patients. KLK4–7-transfected (OV-KLK4–7) and vector-control OV-MZ-6 (OV-VC) ovarian cancer cells were established to select differentially regulated factors. With three independent approaches, PCR arrays, genome-wide microarray and proteome analyses, we identified 10 candidates (MSN, KRT19, COL5A2, COL1A2, BMP5, F10, KRT7, JUNB, BMP4, MMP1). To determine differential protein expression, we performed western blot analyses, immunofluorescence and immunohistochemistry for four candidates (MSN, KRT19, KRT7, JUNB) in cells, tumour xenograft and patient-derived tissues. We demonstrated that KLK4–7 clearly regulates expression of MSN, KRT19, KRT7 and JUNB at the mRNA and protein levels in ovarian cancer cells and tissues. Protein expression of the top-upregulated effectors, MSN and KRT19, was investigated by immunohistochemistry in patients afflicted with serous ovarian cancer and related to KLK4–7 immunoexpression. Significant positive associations were found for KRT19/KLK4, KRT19/KLK5 and MSN/KLK7. These findings imply that KLK4–7 exert key modulatory effects on other cancer-related genes and proteins in ovarian cancer. These downstream effectors of KLK4–7, MSN and KRT19 may represent important therapeutic targets in serous ovarian cancer.
  • References (53)
  • Citations (3)
📖 Papers frequently viewed together
2 Citations
2015
1 Author (Lina Seiz)
78% of Scinapse members use related papers. After signing in, all features are FREE.
References53
Newest
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 47
#2Kimberly D. Miller Mph (ACS: American Cancer Society)H-Index: 2
Last. Ahmedin Jemal Dvm (ACS: American Cancer Society)H-Index: 4
view all 3 authors...
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the Nation...
3,124 CitationsSource
Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data, available through 2014, were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data, available through 2015, were collected by the Nation...
4,299 CitationsSource
#1Munasinghage Lakmali Silva (NIH: National Institutes of Health)H-Index: 3
#2Judith A. Clements (QUT: Queensland University of Technology)H-Index: 54
Introduction: Kallikrein-related peptidases (KLKs) are a family of serine peptidases that are deregulated in numerous pathological conditions, with a multitude of KLK-mediated functional roles implicated in the progression of cancer. Advances in multidimensional mass spectrometry (MS)-based proteomics have facilitated the quantitative measurement of deregulated KLK expression in cancer, identifying certain KLKs, as well as their substrates, as potential cancer biomarkers. Areas covered: In this ...
1 CitationsSource
#1Takayuki Kawai (Kyoto University)H-Index: 12
#2Kentaro Yasuchika (Kyoto University)H-Index: 3
Last. Shinji Uemoto (Kyoto University)H-Index: 66
view all 16 authors...
The current lack of an easily measurable surrogate marker of cancer stem cells (CSCs) prevents the clinical application of CSCs for hepatocellular carcinoma (HCC). We previously reported that keratin 19 (K19) is a novel HCC-CSC marker associated with transforming growth factor beta (TGFβ)/Smad signaling, and that K19+ HCC-CSCs could be a new therapeutic target of TGFβ receptor 1 inhibitor LY2157299. In this study, we examined whether K19+ HCC-CSCs can be tracked using cytokeratin 19 fragment CYF...
2 CitationsSource
#1Michaela AubeleH-Index: 31
#2Axel WalchH-Index: 56
Last. Manfred SchmittH-Index: 63
view all 12 authors...
Triple-negative breast cancer (TNBC), lacking the steroid hormone receptors ER and PR and the oncoprotein HER2, is characterized by its aggressive pattern and insensitivity to endocrine and HER2-directed therapy. Human kallikrein-related peptidases KLK1-15 provide a rich source of serine protease-type biomarkers associated with tumor growth and cancer progression for a variety of malignant diseases. In this study, recombinant KLK4 protein was generated and affinity-purified KLK4-directed polyclo...
8 CitationsSource
#1M. BartovaH-Index: 2
#2Juraj HlavatyH-Index: 11
Last. Ingrid WalterH-Index: 26
view all 7 authors...
Ezrin, radixin, moesin (ERM) are important membrane-cytoskeletal crosslinkers and are suggested to play important role in cancer progression and metastasis. Even though ERM proteins were generally considered to be functionally redundant and the most studied was ezrin, recent studies highlight their distinct roles in metastatic process. Little information is available regarding the role of individual ERM proteins and their phosphorylated forms in human breast cancer. Our study is the first to exa...
7 CitationsSource
#1Yuanyuan QinH-Index: 3
#2Weilong ChenH-Index: 3
Last. Chao-Shi NiuH-Index: 3
view all 11 authors...
8 CitationsSource
#2Yongliang ZhangH-Index: 7
Last. Zihai LiH-Index: 43
view all 13 authors...
12 CitationsSource
#1Mark PinesH-Index: 42
#2Oshrat LeviH-Index: 4
Last. Orna Halevy (HUJI: Hebrew University of Jerusalem)H-Index: 36
view all 7 authors...
Fibrosis is the main complication of muscular dystrophies. We identified moesin, a member of the ezrin-radixin-moesin family, in dystrophic muscles of mice representing Duchenne and congenital muscular dystrophies (DMD and CMD, respectively) and dysferlinopathy, but not in the wild type. High levels of moesin were also observed in muscle biopsy specimens from DMD, Ullrich CMD, and merosin-deficient CMD patients, all of which present high levels of fibrosis. The myofibroblasts, responsible for ex...
5 CitationsSource
In this Review, the authors discuss the emerging roles for members of the transforming growth factor-β (TGFβ) superfamily in regulating immune responses. In particular, they focus on how activin A and bone morphogenetic proteins (BMPs) regulate innate and adaptive immune cells in inflammatory diseases and cancer.
83 CitationsSource
Cited By3
Newest
#1Thomas KryzaH-Index: 5
#2Nathalie Bock (QUT: Queensland University of Technology)H-Index: 8
Last. Judith A. Clements (QUT: Queensland University of Technology)H-Index: 54
view all 19 authors...
Kallikrein‐related peptidase 14 (KLK14) is one of several secreted KLK serine proteases involved in prostate cancer (PCa) pathogenesis. While relatively understudied, recent reports have identified KLK14 as overexpressed during PCa development. However, the modulation of KLK14 expression during PCa progression and the molecular and biological functions of this protease in the prostate tumour microenvironment remain unknown. To determine the modulation of KLK14 expression during PCa progression, ...
Source
#1Jun Lu (SJTU: Shanghai Jiao Tong University)H-Index: 4
Last. Baohui Han (SJTU: Shanghai Jiao Tong University)H-Index: 7
view all 11 authors...
The oral multi-targeted tyrosine kinase inhibitor (TKI) anlotinib is effective for non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, a fraction of patients remains nonresponsive, raising the need of how to identify anlotinib-responsive patients. In the present study, we aimed to screen potential biomarkers for anlotinib-responsive stratification via integrated transcriptome analysis. Comparing with the anlotinib-sensitive lung cancer cell NCI-H1975, we found 1,315 genes...
Source
#1Weiwei Gong (TUM: Technische Universität München)
#2Yueyang Liu (TUM: Technische Universität München)H-Index: 1
Last. Julia Dorn (TUM: Technische Universität München)H-Index: 15
view all 9 authors...
Background In ovarian cancer, dysregulation of mRNA expression of several components of the family of the kallikrein-related peptidases (KLKs) is observed. In this study, we have analyzed the KLK5 mRNA expression pattern in tumor tissue of patients suffering from high-grade serous ovarian cancer stage FIGO III/IV. Moreover, we have correlated the KLK5 mRNA levels with clinical outcome.
Source
#2Yueyang LiuH-Index: 1
Last. Viktor MagdolenH-Index: 39
view all 9 authors...
Source